HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose of review</jats:title> <jats:p>HIV-associated cryptococcal meningitis remains a significant public health problem in parts of Africa and Asia and a major cause of AIDS-related mortality, accounting for 15% of all AIDS-related deaths worldwide. Cryptococcal meningitis is uniformly fatal if untreated, and access to antifungal therapy in regions with the highest burden is often limited. Outcomes with fluconazole monotherapy are poor, and induction treatment with amphotericin B and high-dose fluconazole for 2 weeks is associated with significant drug-related toxicities and prolonged hospital admissions. This review focuses on the potential of novel short-course and oral combination therapies for cryptococcal meningitis.</jats:p> </jats:sec><jats:sec> <jats:title>Recent findings</jats:title> <jats:p>Recent clinical trials have shown that shorter courses of amphotericin, if paired with oral flucytosine, rather than fluconazole, can achieve non-inferior mortality outcomes. In addition, an oral combination of fluconazole and flucytosine is a potential alternative. Liposomal amphotericin B may further simplify treatment; it is associated with fewer drug-related toxicities, and a recent phase II randomised controlled trial demonstrated that a single, high dose of liposomal amphotericin is non-inferior to 14 standard daily doses at clearing <jats:italic>Cryptococcus</jats:italic> from cerebrospinal fluid. This has been taken forward to an ongoing phase III, clinical endpoint study.</jats:p> </jats:sec><jats:sec> <jats:title>Summary</jats:title> <jats:p>The incidence and mortality associated with cryptococcal meningitis is still unacceptably high. There is evidence supporting the use of short-course amphotericin B and oral combination antifungal treatment regimens for cryptococcal meningitis (CM). Ongoing research into short-course, high-dose treatment with liposomal amphotericin may also help reduce the impact of this devastating disease.</jats:p> </jats:sec>